INDV

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.07
Percentage change 0.61	%

Peers: JNJ VRTX PFE ABBV BMY GILD LLY BIIB TEVA NBIX

| Held by: PDN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	7.11%	Shs Outstand	129.57M	Perf Week	1.94%
Market Cap	1.48B	Forward P/E	6.96	EPS next Y	1.66	Insider Trans	0.00%	Shs Float	119.09M	Perf Month	13.99%
Income	-2.00M	PEG	-	EPS next Q	0.26	Inst Own	74.27%	Short Float	0.67%	Perf Quarter	21.28%
Sales	1.18B	P/S	1.25	EPS this Y	8.54%	Inst Trans	-8.65%	Short Ratio	0.69	Perf Half Y	-30.01%
Book/sh	-1.29	P/B	-	EPS next Y	-2.41%	ROA	-0.12%	Short Interest	0.80M	Perf Year	-22.24%
Cash/sh	2.48	P/C	4.66	EPS next 5Y	2.51%	ROE	12.20%	52W Range	7.33 - 23.22	Perf YTD	-24.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-62.20%	ROI	-1.94%	52W High	-50.17%	Beta	0.85
Dividend TTM	-	Quick Ratio	0.65	Sales past 5Y	3.60%	Gross Margin	78.95%	52W Low	57.84%	ATR (14)	0.37
Dividend Ex-Date	Jun 16, 2016	Current Ratio	0.83	EPS Y/Y TTM	98.62%	Oper. Margin	20.71%	RSI (14)	65.74	Volatility	2.49% 3.27%
Employees	1164	Debt/Eq	-	Sales Y/Y TTM	13.53%	Profit Margin	-0.17%	Recom	1.00	Target Price	17.41
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	103.05%	Payout	-	Rel Volume	0.25	Prev Close	11.50
Sales Surprise	1.33%	EPS Surprise	32.78%	Sales Q/Q	13.28%	Earnings	Oct 24 BMO	Avg Volume	1.16M	Price	11.57
SMA20	4.52%	SMA50	16.43%	SMA200	-18.49%	Trades		Volume	287,495	Change	0.61%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	Piper Sandler	Overweight	$22
Apr-03-24	Initiated	Craig Hallum	Buy	$37
Jul-13-23	Initiated	Northland Capital	Outperform	$35

Nov-23-24 02:01AM	Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
Nov-19-24 12:52PM	Rapid Initiation with Once-monthly SUBLOCADE Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 (PR Newswire)
Nov-07-24 02:24PM	Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior (PR Newswire) +16.34%
Oct-30-24 12:30PM	Indivior Highlights Growing Body of Data on SUBLOCADE (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month (PR Newswire)
Oct-25-24 03:07AM	Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ... (GuruFocus.com)
07:05AM	Loading…
Oct-24-24 07:05AM	Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
02:00AM	Indivior Announces Q3 2024 Financial Results (PR Newswire)
Oct-23-24 09:09AM	Indivior PLC (INDV) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Oct-17-24 05:03PM	Two Seas Capital LP Increases Stake in Indivior PLC (GuruFocus.com) +5.53%
Oct-12-24 08:35AM	Indivior price target lowered to $16 from $20 at Craig-Hallum (TipRanks)
Oct-11-24 03:00AM	Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ... (GuruFocus.com) -6.52%
Oct-10-24 09:28AM	Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details (Benzinga) -15.47%
07:00AM	Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion (PR Newswire)
Oct-07-24 11:30AM	Indivior's SUBLOCADE Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review (PR Newswire)
Oct-01-24 03:00AM	Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ... (GuruFocus.com)
02:00PM	Loading…
Sep-23-24 02:00PM	Top 3 Health Care Stocks That May Explode This Month (Benzinga)
Sep-17-24 08:30AM	Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV (PR Newswire)
Sep-13-24 05:45AM	Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV (PR Newswire)
Sep-11-24 08:15AM	Indivior PLC Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INDV (PR Newswire)
Sep-06-24 05:45AM	Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV (PR Newswire) -6.67%
Sep-04-24 02:00AM	Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder (PR Newswire)
Aug-27-24 08:48AM	Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder (Benzinga)
Aug-26-24 10:30AM	Indivior Announces BARDA's First Order of OPVEE to Combat Opioids and Aid in National Preparedness (PR Newswire)
Aug-08-24 12:38PM	Shareholders of Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights INDV (GlobeNewswire)
Jul-26-24 10:44AM	Indivior reaches $86 million opioid settlement with 16 US states (Reuters)
Jul-25-24 07:05AM	Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates (Zacks) +20.31%
02:10AM	Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame (PR Newswire)
02:00AM	Indivior Announces Q2 2024 Financial Results (PR Newswire)
Jul-18-24 10:01AM	Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-10-24 12:57PM	Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View (Zacks)
08:25AM	Loading…
Jul-09-24 08:25AM	Why Is Indivior (INDV) Stock Down 37% Today? (InvestorPlace) -33.57%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
02:00AM	Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT (PR Newswire)
Jul-03-24 02:39PM	Indivior CEO Expects Ongoing U.S. Opioid Crisis to Drive Sales Growth (The Wall Street Journal)
Jun-18-24 03:40PM	Indivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest (PR Newswire)
Jun-10-24 02:30PM	Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder (PR Newswire)
May-24-24 09:06AM	Indivior CEO Mark Crossley on combatting the opioid crisis with new drugs (CNBC TV)
May-23-24 07:02AM	Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance (PR Newswire)
Apr-26-24 01:01PM	Indivior PLC (INDV) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges with ... (GuruFocus.com)
Apr-25-24 07:53AM	INDV Stock Earnings: Indivior Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.29%
07:05AM	Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates (Zacks)
04:38AM	UPDATE 1-UK-listed drugmaker Indivior seeks shareholder nod for US listing (Reuters)
03:48AM	Drugmaker Indivior to seek shareholder nod on shifting primary listing to US (Reuters)
03:44AM	Indivior Confirms Plan to Switch Listing From London to New York (Bloomberg)
02:00AM	Indivior Announces Q1 2024 Financial Results (PR Newswire)
Apr-04-24 09:27AM	Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Mar-19-24 09:55AM	Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-11-24 02:43PM	Indivior Announces Publication Demonstrating that OPVEE (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone (PR Newswire)
Mar-07-24 11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 02:02AM	Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation (PR Newswire)
Feb-23-24 06:54AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Feb-22-24 06:02AM	London Risks Losing Another Major Company to New York Stock Exchange (Bloomberg) +21.71%
05:21AM	Fresh blow for London market as drug maker joins exodus to New York (The Telegraph)
03:21AM	UPDATE 2-Drugmaker Indivior consults on moving primary listing from London to US (Reuters)
02:59AM	Indivior plans shifting primary listing to U.S. (Reuters)
02:00AM	Indivior Announces Q4 / FY 2023 Financial Results (PR Newswire)
Nov-13-23 09:35AM	Indivior PLC (INDV) Loses -17.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-09-23 07:15AM	Indivior PLC (INDV) Tops Q3 Earnings and Revenue Estimates (Zacks) -5.47%
02:05AM	Indivior Announces Q3 2023 Financial Results (PR Newswire)
Oct-23-23 11:35AM	Unveiling Indivior PLC (INDV)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com) +5.91%
02:36AM	Indivior to pay $385 million to end final Suboxone monopoly lawsuits (Reuters)
02:21AM	UPDATE 2-Indivior to pay $385 mln to end final Suboxone monopoly lawsuits (Reuters)
Oct-11-23 04:20PM	Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals (PR Newswire)
Oct-02-23 11:50AM	Indivior PLC (INDV): Unveiling Its Market Value (GuruFocus.com) -5.20%
Sep-26-23 02:30PM	Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada (PR Newswire)
Sep-25-23 11:53AM	Unveiling Indivior PLC (INDV)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-07-23 11:42AM	Indivior PLC (INDV)'s True Worth: A Complete Analysis of Its Market Value (GuruFocus.com)
Aug-29-23 08:50AM	Indivior PLC (INDV) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Aug-21-23 02:46PM	Indivior to pay $30 million to settle health plans' Suboxone claims (Reuters) +6.05%
02:02AM	Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims (PR Newswire)
Jul-27-23 02:00AM	Indivior Announces Q2/H1 2023 Financial Results (PR Newswire)
Jun-14-23 01:53PM	Indivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence (PR Newswire)

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Indivior Plc

Upgrade your FINVIZ experience